FDA approves a second Alzheimer's drug that can modestly slow disease

U.S. health officials have approved a new Alzheimer’s drug that can modestly slow the disease. It's only the second drug that's been convincingly shown to slow the memory-destroying condition. The Food and Drug Administration approved Eli Lilly's medication Tuesday for patients with early or mild cases of dementia caused by Alzheimer's. Kisunla is not a cure and slows worsening memory and cognitive problems by about seven months. The FDA approved a similar drug, Leqembi, from a Japanese drugmaker last year. Lilly's drug has several possible advantages to that medicine, including requiring only one infusion per month instead of two.